Article
Biochemistry & Molecular Biology
Lanxiang Huang, Yuan Rong, Xuan Tang, Kezhen Yi, Peng Qi, Jinxuan Hou, Weihuang Liu, Yuan He, Xing Gao, Chunhui Yuan, Fubing Wang
Summary: By loading immunogenic cell death inducers into breast cancer-derived exosomes, a DC vaccine called HELA-Exos was created. HELA-Exos exhibited high efficacy in inducing immune cell death in breast cancer cells and activating immune responses that suppressed tumor growth.
Article
Engineering, Biomedical
Tianlin Zhou, Jinrong Peng, Ying Hao, Kun Shi, Kai Zhou, Yun Yang, Chengli Yang, Xinlong He, Xinmian Chen, Zhiyong Qian
Summary: The study developed a novel tumor vaccine named Man-EG7/CH@CpG using a biomaterial-based strategy, which showed enhanced anti-tumor effects in lymphoma prevention and treatment models. A combination therapy incorporating a chemotherapeutic drug (doxorubicin) into the vaccination process achieved a tumor inhibition rate of approximately 85%, surpassing the efficacy of mono-chemotherapy or mono-immunotherapy. This strategy may offer a new direction for tumor vaccine development and prioritization of immuno-chemotherapy for Non-Hodgkin lymphoma.
BIOACTIVE MATERIALS
(2021)
Article
Immunology
Marta Calvet-Mirabent, Daniel T. Claiborne, Maud Deruaz, Serah Tanno, Carla Serra, Cristina Delgado-Arevalo, Ildefonso Sanchez-Cerrillo, Ignacio de Los Santos, Jesus Sanz, Lucio Garcia-Fraile, Francisco Sanchez-Madrid, Arantzazu Alfranca, Maria Angeles Munoz-Fernandez, Todd M. Allen, Maria J. Buzon, Alejandro Balazs, Vladimir Vrbanac, Enrique Martin-Gayo
Summary: The combination of 2‘3’-c ' diAM(PS)2 and Poly I:C as adjuvants can enhance DCs' ability to induce polyfunctional HIV-1 specific CD8(+) T-cell responses, reducing the severity of CD4(+) T-cell depletion following HIV-1 infection, and preserving the specific polyfunctional responses of CD8(+) T cells. The priming of DCs with PolyI:C and STING agonists may be useful for future HIV-1 vaccine studies.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2022)
